Valirx (VAL)

 

VAL Share PerformanceMore

52 week high7.3830 13/12/17
52 week low0.9000 15/11/17
52 week change -0.7500 (-12.00%)
4 week volume1,222,842,586 20/11/17

Media for (VAL)

Presenter: Suzanne Dilly
12/12/2017
Presenter: Suzanne Dilly
27/09/2017

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Exercise of Warrants and Issue of Equity

RNS Number: 4327Z ValiRx PLC 15 December 2017 VALIRX PLC ("ValiRx" or the "Company") EXERCISE OF WARRANTS AND ISSUE OF EQUITY London, UK ., 15 December 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, has received notifications of the exercise of warrants over 3,000,000 ordinary shares at an exercise price of 1p and...

ValiRx releases encouraging test results

ValiRx said it had generated further positive results from tests of a lung cancer treatment. Further to the release of pharm...

ValiSeek Clinical Development Update

RNS Number: 0239Z ValiRx PLC 12 December 2017 VALIRX PLC ("ValiRx", the "Company" or the "Group") VALISEEK CLINICAL DEVELOPMENT UPDATE "Positive Formal Data Release Pertaining to Disease Impact from VAL401 Phase II Clinical Trial " London, UK ., 12 December 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company , is ...

ValiRx - ValiSeek Clinical Development Update

Loan Note Conversion and Issue of Equity

RNS Number: 0044Z ValiRx PLC 11 December 2017 Va li R x P lc ("ValiRx" or "the Company" or "the Group") Loan Note Conversion and Issue of Equity London, UK ., 11 December 2017: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines tow...

Shareholder Circular and Notice of General Meeting

RNS Number: 4819Y ValiRx PLC 06 December 2017 VALIRX PLC ("ValiRx" or "the Company") SHAREHOLDERCIRCULAR AND NOTICE OF GENERAL MEETING London,UK, 6 December 2017:ValiRxPlc (AIM: VAL), a clinical stage biotechnologyannounces that it has recently publishedand posted to shareholders a circularand notice convening a GeneralM...

Issue of Equity

RNS Number: 0227Y ValiRx PLC 30 November 2017 30 November 2017 ValiRx Plc ("ValiRx" or the "Company") Issue of Equity ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, is pleased to announce it has conditionally raised 1.0 million of gross proceeds through the issue of 80,000,000 new ordinary shares at a price of 1.25 pence per share (" Placing...

Holding(s) in Company

RNS Number: 9770W ValiRx PLC 20 November 2017 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Valirx PLC 1b. Please ...

Fundamental DataMore

EPS-8.54
Dividend yield0 %

Latest discussion posts More

  • Re: RNS today

    Limit order to buy a few @ 4.5p filled @ 8:30. Bit of a bounce since, but anticipate the possibility of SP to fall back if no +ve news soon. VAL isn?t the only company ...
    15-Dec-2017
    Taddish
  • RNS today

    Of little interest or concern this issue of shares is a tiddler. Look out for more RNS of this nature in December, maybe hidden between Christmas and the New Year? Only ...
    15-Dec-2017
    Tired and Confused
  • Re: VAL201

    https://clinicaltrials.gov/ct2/show/NCT02280317?term=valirx&rank=1 The estimated study completion date is still stated as December 2017. That the date that they complete ...
    14-Dec-2017
    John6185

Users' HoldingsMore

Users who hold Valirx also hold..

Codes & Symbols

ISINGB00BWWYSP41
SymbolsVAL, LSE:VAL, VAL.L, VAL:LN, LON:VAL, XLON:VAL

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account